DexCom Inc. (DXCM): Price and Financial Metrics
DXCM Price/Volume Stats
| Current price | $119.71 | 52-week high | $126.59 |
| Prev. close | $125.38 | 52-week low | $67.11 |
| Day low | $117.74 | Volume | 3,099,500 |
| Day high | $126.19 | Avg. volume | 2,445,982 |
| 50-day MA | $118.57 | Dividend yield | N/A |
| 200-day MA | $109.02 | Market Cap | 46.40B |
DXCM Stock Price Chart Interactive Chart >
DXCM POWR Grades
- DXCM scores best on the Sentiment dimension, with a Sentiment rank ahead of 91.24% of US stocks.
- The strongest trend for DXCM is in Stability, which has been heading up over the past 179 days.
- DXCM ranks lowest in Momentum; there it ranks in the 6th percentile.
DXCM Stock Summary
- With a market capitalization of $45,248,706,273, DEXCOM INC has a greater market value than 95.21% of US stocks.
- With a price/earnings ratio of 154.7, DEXCOM INC P/E ratio is greater than that of about 96.71% of stocks in our set with positive earnings.
- Price to trailing twelve month operating cash flow for DXCM is currently 60.02, higher than 93.73% of US stocks with positive operating cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to DEXCOM INC are RMD, TEL, EBAY, A, and ON.
- DXCM's SEC filings can be seen here. And to visit DEXCOM INC's official web site, go to www.dexcom.com.
DXCM Valuation Summary
- DXCM's price/earnings ratio is 153.3; this is 536.1% higher than that of the median Healthcare stock.
- Over the past 220 months, DXCM's EV/EBIT ratio has gone up 136.1.
Below are key valuation metrics over time for DXCM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DXCM | 2023-05-23 | 14.8 | 20.1 | 153.3 | 115.7 |
| DXCM | 2023-05-22 | 15.3 | 20.7 | 158.1 | 119.2 |
| DXCM | 2023-05-19 | 15.0 | 20.3 | 155.2 | 117.1 |
| DXCM | 2023-05-18 | 15.3 | 20.7 | 157.7 | 119.0 |
| DXCM | 2023-05-17 | 15.2 | 20.6 | 157.2 | 118.5 |
| DXCM | 2023-05-16 | 15.2 | 20.6 | 157.2 | 118.6 |
DXCM Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 263.1%.
- Its 3 year net cashflow from operations growth rate is now at 238%.
- The 2 year net cashflow from operations growth rate now stands at 59.46%.
The table below shows DXCM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 2,909.8 | 669.5 | 341.2 |
| 2022-09-30 | 2,792.8 | 642.8 | 230 |
| 2022-06-30 | 2,673.4 | 596.9 | 199.7 |
| 2022-03-31 | 2,572.3 | 485.7 | 211.7 |
| 2021-12-31 | 2,448.5 | 442.5 | 154.7 |
| 2021-09-30 | 2,319.2 | 508.7 | 529.3 |
DXCM's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DXCM has a Quality Grade of B, ranking ahead of 87.89% of graded US stocks.
- DXCM's asset turnover comes in at 0.517 -- ranking 89th of 186 Medical Equipment stocks.
- VRAY, ZYXI, and SRTS are the stocks whose asset turnover ratios are most correlated with DXCM.
The table below shows DXCM's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.517 | 0.693 | 0.081 |
| 2021-06-30 | 0.510 | 0.692 | 0.077 |
| 2021-03-31 | 0.506 | 0.675 | 0.070 |
| 2020-12-31 | 0.547 | 0.664 | 0.077 |
| 2020-09-30 | 0.597 | 0.654 | 0.089 |
| 2020-06-30 | 0.651 | 0.639 | 0.090 |
DXCM Price Target
For more insight on analysts targets of DXCM, see our DXCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $530.60 | Average Broker Recommendation | 1.36 (Strong Buy) |
DexCom Inc. (DXCM) Company Bio
Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. (Source:Wikipedia)
Latest DXCM News From Around the Web
Below are the latest news stories about DEXCOM INC that investors may wish to consider to help them evaluate DXCM as an investment opportunity.
Dow Jones Giant McDonald's Tests Key Support Level; Tesla Stock In Buy RangeDow Jones leader McDonald's is trying to find support around a key level, while Tesla stock is in buy range past its latest entry. |
Dow Jones Futures Fall: Market Rally Retreats On Apple; 5 Stocks In Buy AreasThe market rally saw modest losses Monday as Apple dipped after unveiling its $3,499 Vision Pro goggles. Tesla leads five stocks in buy areas. |
10 Top-Rated Stocks Billionaires Are Loading Up OnIn this piece, we will take a look at the ten top rated stocks billionaires are loading up on. For more stocks, head on over to 5 Top-Rated Stocks Billionaires Are Loading Up On. The U.S. economy has undergone several shocks over the past couple of years. This turmoil started after the onset of the […] |
Have $1,500? 2 Top Growth Stocks to Buy and Hold for the Long HaulIn a time where recession concerns remain for many investors, and the market is continuing to deal with regular bouts of volatility, it can be easy to lose sight of your long-term investment horizon and get caught up in the day-to-day machinations of the market. If you're looking for two compelling businesses to invest $1,500 in this month, here are two names to consider hitting the buy button on right now. Fiverr (NYSE: FVRR) continues to help customers, from small enterprises to massive brands, connect with freelancers that meet their business needs. |
Dow Jones Falls As Apple Unveils These Products; This Stock Soars After Cathie Wood Sells ItThe Dow Jones slid while Apple stock reversed despite unveiling the Vision Pro headset. A Cathie Wood stock popped higher. |
DXCM Price Returns
| 1-mo | 0.05% |
| 3-mo | 11.08% |
| 6-mo | 2.79% |
| 1-year | 56.54% |
| 3-year | 29.90% |
| 5-year | 414.88% |
| YTD | 5.71% |
| 2022 | -15.64% |
| 2021 | 45.23% |
| 2020 | 69.02% |
| 2019 | 82.59% |
| 2018 | 108.75% |
Continue Researching DXCM
Want to do more research on Dexcom Inc's stock and its price? Try the links below:Dexcom Inc (DXCM) Stock Price | Nasdaq
Dexcom Inc (DXCM) Stock Quote, History and News - Yahoo Finance
Dexcom Inc (DXCM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...